ALKS 2680 Improves Wakefulness in Narcolepsy Type 2 and IH
Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.
Source: sleepreviewmag.com
Page 2 - Wakefulness Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Wakefulness Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Wakefulness Test Today - Breaking & Trending Today
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says - Alkermes (NASDAQ:ALKS)
ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.
Source: benzinga.com
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b,…
Source: biztoc.com
The Role of Orexin Receptor 2 Agonists in Sleep and Narcolepsy Type 1
Elena Koundourakis, the head of the Orexin Franchise Development and Portfolio Strategy at Takeda, shares her thoughts on the recent positive topline results from a phase 2 trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Source: psychiatrictimes.com
Takeda's Oral Orexin Agonist to Enter Phase 3 Narcolepsy Trials
Takeda announced results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Source: sleepreviewmag.com